N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use
NCT ID: NCT04627922 Phase: PHASE4 Status: COMPLETED Enrollment: 59 Completion: 2025-06-30
Conditions
Cannabis Use, Tobacco Use Disorder, Drug Use Disorder
Interventions
N-Acetyl cysteine, Placebo comparator, Cognitive behavioral therapy (CBT)
Summary
Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.
Primary Outcome
Change in the mean days of cannabis use over time